Paricalcitol for secondary hyperparathyroidism in renal transplantation. - Wikidata - wikimedia - TriplyDB

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

http://www.wikidata.org/entity/Q35550544

about

Mineral and bone disorder after kidney transplantation Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system Impact of seasonality on the dynamics of native Vitamin D repletion in long-term renal transplant patients Phosphate and FGF-23 homeostasis after kidney transplantation.Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.Current evidence on vitamin D deficiency and kidney transplant: What's new?CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health.Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion.Bone Disease after Kidney Transplantation.Effect of Twice-Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial.Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study.Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis.Evolution of bone disease after kidney transplantation: A prospective histomorphometric analysis of trabecular and cortical bone.Vitamin D and Uterine Fibroids-Review of the Literature and Novel Concepts Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score

P2860

Q26771398-689C5BA4-DEFE-4371-B27D-3053C39A7B69 Q26822500-3AD91A4B-48E0-4655-8CE0-6B0880138476 Q33783035-581E577E-37E2-4007-92B5-047009F5CEFD Q38594874-9F89ABB0-9C16-400E-B976-E86B0F3CB1F8 Q38691202-ABE7D229-35F7-490D-850A-F48315B777D3 Q38803449-AD457656-2CF7-4876-916D-A132AADFEEEB Q39172404-36C5D10A-3A97-44D3-8216-1B2F36D629F2 Q39247900-7123717C-D933-43E5-B037-A8747C87CCAA Q39447041-67A452D3-B0A8-4BE1-B489-605119811E27 Q39970839-20E6A745-5970-433D-9BA9-D8E57A198D36 Q40853318-A0DCB339-1D66-4D62-A2BE-64BECFCE363E Q48242270-71CB97C6-D9FA-426A-B103-88CA83C2D9DC Q49449891-FFA69C77-E393-48DB-91CB-9EBB1027AD30 Q51823258-22009F65-D3AF-460D-8466-754C7368F54A Q53412995-49E52991-D0E3-49CD-9B48-21AEF02DCF49 Q57176044-F542ED38-408B-4A73-A2C8-641A0A8F3583 Q58721207-0230AD03-9F9C-4A57-8E3F-7FF2F5A135A0

P2860

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

http://www.wikidata.org/entity/Q35550544

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

@ast

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

@en

type

label

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

@ast

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

@en

prefLabel

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

@ast

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

@en

P1433

Q35550544-5555B418-4363-476E-9A35-AA68E459C56D

P1476

Q35550544-0531C4D4-4327-4EF7-9C6F-72160DE9AC02

P2093

Q35550544-2FFBCE4E-55FD-4E68-BD1F-CB00DAA8E757

Q35550544-41083613-5676-419F-AF7D-30B8B48EC96E

Q35550544-56EC1D6A-7C48-42B6-8E02-99ECF7D3F313

Q35550544-62E8839A-BC3D-40D6-A6A2-65B5DB5D819C

Q35550544-9B4640DA-A533-4686-993E-20EC2406E870

Q35550544-C697CEE3-69A0-43BD-AD47-C4895F6D6D2F

Q35550544-C8F52427-2186-4E41-9753-DF7102AD440B

Q35550544-DBF3D897-666B-496C-BCEA-D5F5268F7493

Q35550544-DCA59FAC-5AFD-4F6B-BE6F-078EE7BD490A

Q35550544-FF32362B-A6CD-4BC3-81C5-F494C757708B

P2860

Q35550544-01D11F47-BCB8-4F74-861F-7E8367A77A46

Q35550544-07406FED-FCDD-4925-8276-8A195CCCF68D

Q35550544-4A1729AA-824F-43F1-8B5C-AF2AD8F1B559

Q35550544-4F48518C-F7A4-417F-AAB6-C9B18BE0477B

Q35550544-5002913B-D278-4585-A9A3-CF79528D19B8

Q35550544-553C580D-2229-4B38-81CE-D2E83E961889

Q35550544-65EDEFF5-A2ED-42E1-A94B-2FDC9A1B4199

Q35550544-6A07C0A8-F260-4852-AF44-1067F8887FDA

Q35550544-6CA04EAC-2673-4CB9-83D8-DDABBB68C32A

Q35550544-6E2F384A-BCFE-4E2E-93A9-C2C15CA465A5

P304

Q35550544-52E41F1A-BAAD-4AE6-B40A-66BCDC3F3A2A

P31

Q35550544-F86927DF-1CE3-4A01-B6C7-53746C327837

P356

Q35550544-CF120CEE-6BBF-40AB-8C91-6AC1135569C6

P433

Q35550544-4EF46926-5451-4B2A-83C6-207684A25507

P478

Q35550544-E4790439-E22E-462F-85FA-18C6B42AB43A

P50

Q35550544-03D318BD-5C11-486D-B9A7-5DA2BB5A8683

Q35550544-59B44E8C-7D8F-464F-9397-2E12BFF9BD7D

Q35550544-678F98AF-76B6-4DE3-8015-0B017339187E

Q35550544-6B12C452-42D3-43EE-8BD1-72B7A5B59432

Q35550544-7E4552B0-6DDA-4486-83E1-2B2460CB40E8

Q35550544-EC58EF13-4B19-4FBF-94F4-02ABC0131424

P577

Q35550544-6F992D0F-2B42-405E-932A-1204255F5183

P698

Q35550544-EA8043E0-A4F6-45EE-AB4A-A8F45EC45B7A

P921

Q35550544-81542731-FBBF-4961-8A58-FDFEAED6B55C

P932

Q35550544-5D78B273-8AEA-4400-8080-1EC7C5048B04

P356

P1433

Journal of the American Society of Nephrology

P1476

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

@en

P2093

Alessandro Villa

http://www.w3.org/2001/XMLSchema#string

Antonio Cannata

http://www.w3.org/2001/XMLSchema#string

Claudia Ferrer-Siles

http://www.w3.org/2001/XMLSchema#string

Davide Martinetti

http://www.w3.org/2001/XMLSchema#string

Eliana Gotti

http://www.w3.org/2001/XMLSchema#string

Flavio Gaspari

http://www.w3.org/2001/XMLSchema#string

Jorge Reyes Loaeza

http://www.w3.org/2001/XMLSchema#string

Maria Rosa Caruso

http://www.w3.org/2001/XMLSchema#string

Norberto Perico

http://www.w3.org/2001/XMLSchema#string

Silvia Prandini

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced fracture risk with early corticosteroid withdrawal after kidney transplant.

Inflammation, coronary artery calcification and cardiovascular events in incident renal transplant recipients.

Calcium metabolism and skeletal problems after transplantation.

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.

Bone disease after renal transplantation.

Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product.

The fate of bone after renal transplantation.

P304

1205-1214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2013111185

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Remuzzi

Matias Trillini

Karen Courville de Vaccaro

Piero Ruggenenti

Monica Cortinovis

P577

2014-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25194004

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism

P932

4413751

http://www.w3.org/2001/XMLSchema#string